Quizzes

True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...

True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...

True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...

True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...

Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?

The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?

The phase 3 SERENA-6 trial evaluated an early switch to camizestrant plus continued CDK4/6 inhibition at the time of ESR1 mutation emergence in patients with HR-positive, HER2-negative advanced breast cancer.Which of the following best...

According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?

Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?